About: http://data.cimple.eu/news-article/9f0c889d2b275044eab2c14f057fabead0e125f2281222cba868a3f8     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • US pharmaceutical company Eli Lilly's combination of two synthetic antibodies against Covid-19 reduced hospitalizations and deaths by 70 percent in high-risk patients with recent positive tests, the company said Tuesday. "Bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalizations and death in high-risk COVID-19 patients," Lilly's chief scientific officer Daniel Skovronsky said. The results meant that the phase 3 trial involving 1,035 people achieved its main goal, and the study also met its secondary goals of reducing patients' viral load and their time to recover from the disease. Patients were assigned either a placebo or the combination of bamlanivimab and etesevimab, the two antibodies, at 2.8 grams each. There were 11 deaths or hospitalizations in the patients who received the therapy, or 2.1 percent of that group. In the placebo arm, there were 36 deaths or hospitalizations, or 7.0 percent of the group. The therapy thus represented a risk reduction of 70 percent, and the result was statistically significant, meaning it was unlikely to have occurred by chance. There were 10 deaths total, all of which occurred in patients taking placebo, and none in the therapy group. The company said it would continue to study the drug in another trial to examine whether lower doses would yield the same impact. Monoclonal antibodies are lab-made versions of the body's natural infection-fighting defenses. Many scientists have welcomed their Covid fighting potential, and both Lilly and biotech firm Regeneron have received emergency use authorizations for their treatments. But their uptake has been limited in the US by several factors, from a lack of patient interest to not enough staffing and logistical capacity by hospitals to administer them. In its press release, Lilly acknowledged some of these difficulties. "Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration," the statement said. As a result, the company is working with the Food and Drug Administration to potentially reduce the infusion time from the current 60 minutes to as little as 16 minutes. ia/wat
schema:headline
  • Lilly Covid antibodies cut hospitalizations and deaths
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...romotesConspiracy
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software